Protalix BioTherapeutics (PLX) Competitors

$2.62 -0.08 (-2.96%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$2.61 -0.01 (-0.38%)

As of 10/16/2026 07:30 PM Eastern

PLX vs. MLTX, KURA, RIGL, JBIO, and ALMS

Should you buy Protalix BioTherapeutics stock or one of its competitors? Protalix BioTherapeutics's main competitors and comparable companies include MoonLake Immunotherapeutics (MLTX), Kura Oncology (KURA), Rigel Pharmaceuticals (RIGL), Jade Biosciences (JBIO), and Alumis (ALMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protalix BioTherapeutics compare to MoonLake Immunotherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Protalix BioTherapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Protalix BioTherapeutics presently has a consensus price target of $12.00, indicating a potential upside of 358.02%. MoonLake Immunotherapeutics has a consensus price target of $28.50, indicating a potential upside of 198.43%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
MoonLake Immunotherapeutics	3 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.43

Protalix BioTherapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.62	$8.31M	$0.23	11.39
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 1 mentions for MoonLake Immunotherapeutics and 0 mentions for Protalix BioTherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 1.37 beat Protalix BioTherapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
MoonLake Immunotherapeutics	Positive

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

MoonLake Immunotherapeutics beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Kura Oncology?

Protalix BioTherapeutics (NYSE:PLX) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Kura Oncology had 8 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 8 mentions for Kura Oncology and 0 mentions for Protalix BioTherapeutics. Kura Oncology's average media sentiment score of 0.22 beat Protalix BioTherapeutics' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Kura Oncology	Neutral

Protalix BioTherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 358.02%. Kura Oncology has a consensus target price of $25.35, suggesting a potential upside of 179.22%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Protalix BioTherapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Protalix BioTherapeutics has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.62	$8.31M	$0.23	11.39
Kura Oncology	$67.48M	11.97	-$278.67M	-$3.37	N/A

Protalix BioTherapeutics has a net margin of -21.03% compared to Kura Oncology's net margin of -384.30%. Protalix BioTherapeutics' return on equity of -30.89% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Kura Oncology	-384.30%	-207.18%	-45.17%

Protalix BioTherapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Protalix BioTherapeutics beats Kura Oncology on 9 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Protalix BioTherapeutics (NYSE:PLX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Protalix BioTherapeutics presently has a consensus price target of $12.00, indicating a potential upside of 358.02%. Rigel Pharmaceuticals has a consensus price target of $59.00, indicating a potential upside of 28.34%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Protalix BioTherapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Rigel Pharmaceuticals had 4 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for Rigel Pharmaceuticals and 0 mentions for Protalix BioTherapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.49 beat Protalix BioTherapeutics' score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Rigel Pharmaceuticals	Neutral

Protalix BioTherapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has higher revenue and earnings than Protalix BioTherapeutics. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.62	$8.31M	$0.23	11.39
Rigel Pharmaceuticals	$294.28M	2.89	$367.02M	$16.32	2.82

Rigel Pharmaceuticals has a net margin of 116.30% compared to Protalix BioTherapeutics' net margin of -21.03%. Rigel Pharmaceuticals' return on equity of 22.95% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Summary

Rigel Pharmaceuticals beats Protalix BioTherapeutics on 14 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Jade Biosciences?

Protalix BioTherapeutics (NYSE:PLX) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Jade Biosciences' average media sentiment score of 1.82 beat Protalix BioTherapeutics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Jade Biosciences	Very Positive

Protalix BioTherapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.62	$8.31M	$0.23	11.39
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

Jade Biosciences has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Jade Biosciences	N/A	-49.11%	-45.62%

Protalix BioTherapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 358.02%. Jade Biosciences has a consensus price target of $51.75, suggesting a potential upside of 284.19%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Protalix BioTherapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

Protalix BioTherapeutics beats Jade Biosciences on 8 of the 14 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Alumis?

Alumis (NASDAQ:ALMS) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Protalix BioTherapeutics has a net margin of -21.03% compared to Alumis' net margin of -5,933.46%. Protalix BioTherapeutics' return on equity of -30.89% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 33.7% of Alumis shares are owned by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alumis has a beta of -0.38, indicating that its share price is 138% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

Protalix BioTherapeutics has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	32.94	-$243.32M	-$3.86	N/A
Protalix BioTherapeutics	$80.62M	2.62	$8.31M	$0.23	11.39

In the previous week, Alumis had 6 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 6 mentions for Alumis and 0 mentions for Protalix BioTherapeutics. Alumis' average media sentiment score of 0.68 beat Protalix BioTherapeutics' score of 0.00 indicating that Alumis is being referred to more favorably in the media.

Company	Overall Sentiment
Alumis	Positive
Protalix BioTherapeutics	Neutral

Alumis presently has a consensus target price of $33.27, suggesting a potential upside of 443.67%. Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 358.02%. Given Alumis' higher possible upside, equities analysts plainly believe Alumis is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Protalix BioTherapeutics beats Alumis on 9 of the 17 factors compared between the two stocks.

Get Protalix BioTherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLX vs. The Competition

Export

Metric	Protalix BioTherapeutics	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$211.10M	$3.95B	$7.45B	$23.17B
Dividend Yield	N/A	3.64%	2.50%	3.69%
P/E Ratio	-20.15	12.55	275.00	28.15
Price / Sales	2.62	1,175.02	566.23	20.26
Price / Cash	17.80	122.10	76.54	36.50
Price / Book	5.57	15.94	10.31	4.69
Net Income	$8.31M	-$22.69M	$3.51B	$1.07B
7 Day Performance	-5.76%	-8.71%	-5.47%	-0.83%
1 Month Performance	-2.96%	-15.43%	-9.66%	-3.17%
1 Year Performance	40.86%	1.39%	0.73%	6.79%

Protalix BioTherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLX Protalix BioTherapeutics	2.3945 of 5 stars	$2.62 -3.0%	$12.00 +358.0%	+9.2%	$211.10M	$80.62M	N/A	226
MLTX MoonLake Immunotherapeutics	3.1347 of 5 stars	$10.41 -2.5%	$28.50 +173.8%	+1.8%	$885.96M	N/A	N/A	130
KURA Kura Oncology	3.5942 of 5 stars	$9.83 -5.5%	$25.69 +161.3%	-10.4%	$874.48M	$67.48M	N/A	260	Analyst Forecast
RIGL Rigel Pharmaceuticals	4.323 of 5 stars	$47.14 -3.4%	$59.00 +25.2%	+63.5%	$872.09M	$294.28M	2.89	174	News Coverage Analyst Downgrade
JBIO Jade Biosciences	2.442 of 5 stars	$13.42 -4.1%	$51.75 +285.6%	+37.7%	$853.47M	N/A	N/A	55

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PLX) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protalix BioTherapeutics (PLX) Competitors

PLX vs. MLTX, KURA, RIGL, JBIO, and ALMS

How does Protalix BioTherapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Protalix BioTherapeutics compare to Kura Oncology?

Summary

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Summary

How does Protalix BioTherapeutics compare to Jade Biosciences?

Summary

How does Protalix BioTherapeutics compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protalix BioTherapeutics (PLX) Competitors

PLX vs. MLTX, KURA, RIGL, JBIO, and ALMS

How does Protalix BioTherapeutics compare to MoonLake Immunotherapeutics?

Is PLX or MLTX more profitable?

Which has more volatility and risk, PLX or MLTX?

Do analysts prefer PLX or MLTX?

Which has stronger valuation & earnings, PLX or MLTX?

Does the media refer more to PLX or MLTX?

Do insiders & institutionals hold more shares of PLX or MLTX?

Summary

How does Protalix BioTherapeutics compare to Kura Oncology?

Does the media refer more to PLX or KURA?

Do analysts recommend PLX or KURA?

Which has preferable valuation and earnings, PLX or KURA?

Is PLX or KURA more profitable?

Which has more volatility & risk, PLX or KURA?

Do institutionals and insiders hold more shares of PLX or KURA?

Summary

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Do analysts prefer PLX or RIGL?

Does the media favor PLX or RIGL?

Which has more risk & volatility, PLX or RIGL?

Do institutionals and insiders believe in PLX or RIGL?

Which has higher valuation & earnings, PLX or RIGL?

Is PLX or RIGL more profitable?

Summary

How does Protalix BioTherapeutics compare to Jade Biosciences?

Do institutionals & insiders have more ownership in PLX or JBIO?

Does the media favor PLX or JBIO?

Which has preferable valuation and earnings, PLX or JBIO?

Is PLX or JBIO more profitable?

Which has more volatility and risk, PLX or JBIO?

Do analysts prefer PLX or JBIO?

Summary

How does Protalix BioTherapeutics compare to Alumis?

Is ALMS or PLX more profitable?

Do institutionals & insiders have more ownership in ALMS or PLX?

Which has more risk and volatility, ALMS or PLX?

Which has preferable valuation & earnings, ALMS or PLX?

Does the media prefer ALMS or PLX?

Do analysts prefer ALMS or PLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools